CSIMarket
 
Vectivbio Holding Ag  (VECT)
Other Ticker:  
 
 
Price: $16.8500 $0.00 0.000%
Day's High: $16.88 Week Perf: -0.12 %
Day's Low: $ 16.80 30 Day Perf: 1.51 %
Volume (M): 130 52 Wk High: $ 16.98
Volume (M$): $ 2,197 52 Wk Avg: $12.76
Open: $16.80 52 Wk Low: $7.86



 Market Capitalization (Millions $) 745
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) 27
 Net Income (TTM) (Millions $) -94
 Cash Flow (TTM) (Millions $) 103
 Capital Exp. (TTM) (Millions $) 0

Vectivbio Holding Ag
VectivBio Holding AG is a Swiss clinical-stage biotechnology company focused on developing innovative therapies for the treatment of severe rare diseases. The company aims to address areas of high unmet medical need and improve the lives of patients with debilitating conditions.

VectivBio is primarily dedicated to advancing its lead product candidate, apraglutide, which is being developed for the treatment of short bowel syndrome (SBS). SBS is a rare gastrointestinal disorder characterized by impaired absorption of nutrients due to the surgical removal of a significant portion of the small intestine.

Apraglutide is a novel, long-acting synthetic GLP-2 analog that has shown promise in early clinical trials for SBS patients. The drug works by promoting the repair and growth of the intestinal mucosa, thereby improving nutrient absorption and reducing dependence on parenteral nutrition.

VectivBio is also exploring the potential of apraglutide for the treatment of other rare gastrointestinal diseases, including pediatric SBS and intestinal failure-associated liver disease (IFALD).

The company's vision is to become a leading global biotech company dedicated to developing transformative therapies for severe rare diseases. With a focus on precision medicine and patient-centric approaches, VectivBio aims to make a meaningful impact on the lives of patients suffering from these debilitating conditions.


   Company Address: Aeschenvorstadt 36 Basel 4051
   Company Phone Number: 615513030   Stock Exchange / Ticker: NASDAQ VECT
   VECT is expected to report next financial results on April 18, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cyclo Therapeutics Inc

CYTH Sees Impressive Revenue Surge and Deficit Reduction in Q4 2023

Cyclo Therapeutics Inc, a Biotechnology and Pharmaceuticals company, has shown positive growth in the fourth quarter of 2023, despite industry-wide challenges. In its December 31, 2023 report, the company reported a significant revenue rise of 66.699% to $0.31 million. This increase in revenue has helped the company reduce its losses to $-0.18 per share, down from $-0.48 per share in the same reporting season the previous year.
Unlike many other entities in the Biotechnology and Pharmaceuticals sectors, which are experiencing declining top-line and receding transactions, Cyclo Therapeutics Inc has managed to shine in the fourth quarter. This is a positive development for the company, as it signifies its ability to navigate obstacles and maintain growth.

Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc Reports Operating Deficit of $-18.2 Million in Fourth Quarter of 2023

In the world of biotechnology and pharmaceuticals, Calidi Biotherapeutics Inc has recently announced its financial results for the fourth quarter of 2023. The company reported an operating deficit of $-18.246049 million, a significant increase from the operating deficit of $-2.714765 million in the fourth quarter of 2022.
The net deficit for the financial period ending December 31, 2023, was reported at $-20.699 million, a substantial increase from $-2.587 million in the previous year. Despite these losses, the company did not report any revenue for the financial year 2023, with a bottom-line of $-29.22 million.

Coherus Biosciences Inc

Coherus Biosciences Inc Makes Bold Strategic Move in Divesting Ophthalmology Franchise for $170 Million

Coherus Biosciences, a leading biopharmaceutical company, has recently completed the divestiture of its Ophthalmology Franchise with an upfront cash payment of $170 million. This strategic move aims to strengthen the company's capital structure and focus on its core business areas.
The divestiture of Coherus' Ophthalmology Franchise is a significant step towards streamlining its operations and reallocating resources into key therapeutic areas. By divesting the franchise, the company can optimize its business and concentrate on its primary goal of developing innovative and cost-effective treatment options for patients.

Fresh Tracks Therapeutics Inc

2. The Future of Fresh Tracks Therapeutics Inc: Analyzing Financial Results and Market Suspension

Fresh Tracks Therapeutics Inc: Navigating Challenges and Charting a New Course
As an investor and shareholder of Fresh Tracks Therapeutics Inc, I have closely followed the latest financial results and the recent announcement about the company's stock being suspended from trading on The Nasdaq Capital Market. As an avid reader of The , it is my pleasure to share my interpretation and provide some insights into what these developments might mean for the future of the company.
First and foremost, let's delve into the financial results. Fresh Tracks Therapeutics Inc has certainly shown improvement in its recent fiscal period compared to the previous year. The company managed to reduce its losses per share substantially, from $-1.70 to $-0.12. In addition, EPS fell from $0.32 to $-0.12, indicating a decline in profitability. While it is certainly a step in the right direction to cut down losses, it is important to keep an eye on the declining EPS and explore ways to improve it in the future.

Zivo Bioscience Inc

Zivo Bioscience Inc Reports Revenue Growth in Fourth Quarter of 2023

Zivo Bioscience Inc, a leading biotech/agtech RandD company, has recently made headlines with its announcement of a 1-for-6 reverse stock split. This decision comes as the company seeks to address challenges faced by its shareholders and increase investor confidence. By consolidating shares, this move aims to improve stability and potentially boost shareholder value.
The company, specializing in the development of therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, reported revenue of $0.0118 million in the October to December 31, 2023 period. While there was a net shortfall of $-1.909 million during this time frame, it marks an improvement from the previous year's deficit of $-2.641 million. Looking at the financial results for the entire 2023 fiscal year, Zivo Bioscience Inc reported a shortfall of $-7.78 million and revenue of $0.03 million. The net shortfall per share also increased to $-4.60 from $-0.93 in the prior financial year.






 

Vectivbio Holding Ag's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com